BR112021022629A2 - Derivado de polipeptídeo e método de preparação do mesmo - Google Patents

Derivado de polipeptídeo e método de preparação do mesmo

Info

Publication number
BR112021022629A2
BR112021022629A2 BR112021022629A BR112021022629A BR112021022629A2 BR 112021022629 A2 BR112021022629 A2 BR 112021022629A2 BR 112021022629 A BR112021022629 A BR 112021022629A BR 112021022629 A BR112021022629 A BR 112021022629A BR 112021022629 A2 BR112021022629 A2 BR 112021022629A2
Authority
BR
Brazil
Prior art keywords
polypeptide derivative
preparation
preparing
polypeptide
derivative
Prior art date
Application number
BR112021022629A
Other languages
English (en)
Inventor
Huiling Liu
Song Wu
Wei Chen
Zhenshan Zhang
Original Assignee
Ningbo Kunpeng Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ningbo Kunpeng Biotech Co Ltd filed Critical Ningbo Kunpeng Biotech Co Ltd
Publication of BR112021022629A2 publication Critical patent/BR112021022629A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
    • C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
    • C12Y601/01026—Pyrrolysine-tRNAPyl ligase (6.1.1.26)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

derivado de polipeptídeo e método de preparação do mesmo. são fornecidos um derivado de polipeptídeo e um método de preparação do mesmo. especificamente, é fornecido um derivado de polipeptídeo. resultados experimentais mostram que o derivado de polipeptídeo tem uma meia-vida significativamente prolongada, enquanto mantém atividade biológica. o método de preparação do derivado de polipeptídeo e seu uso em terapia também são revelados.
BR112021022629A 2019-05-10 2020-05-08 Derivado de polipeptídeo e método de preparação do mesmo BR112021022629A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910390476.3A CN111909256A (zh) 2019-05-10 2019-05-10 多肽衍生物及其制备方法
PCT/CN2020/089217 WO2020228610A1 (zh) 2019-05-10 2020-05-08 多肽衍生物及其制备方法

Publications (1)

Publication Number Publication Date
BR112021022629A2 true BR112021022629A2 (pt) 2022-01-04

Family

ID=73242938

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022629A BR112021022629A2 (pt) 2019-05-10 2020-05-08 Derivado de polipeptídeo e método de preparação do mesmo

Country Status (8)

Country Link
US (1) US20220211857A1 (pt)
EP (1) EP3967759A4 (pt)
JP (1) JP7453698B2 (pt)
CN (2) CN111909256A (pt)
AU (1) AU2020276560A1 (pt)
BR (1) BR112021022629A2 (pt)
CA (1) CA3139826A1 (pt)
WO (1) WO2020228610A1 (pt)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI362392B (en) * 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2007130453A2 (en) 2006-05-02 2007-11-15 Allozyne, Inc. Non-natural amino acid substituted polypeptides
US8962794B2 (en) 2007-08-15 2015-02-24 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
US8637306B2 (en) 2008-12-10 2014-01-28 The Scripps Research Institute Production of carrier-peptide conjugates using chemically reactive unnatural amino acids
US20130078671A1 (en) * 2011-03-25 2013-03-28 The Texas A&M University System Incorporation of two different noncanonical amino acids into a single protein
TW201311679A (zh) * 2011-08-04 2013-03-16 Takeda Pharmaceutical 含氮雜環化合物
CN102504022A (zh) * 2011-11-30 2012-06-20 苏州元基生物技术有限公司 含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法
EP2898085B1 (en) * 2012-09-24 2019-01-23 MedImmune Limited Cell lines
CN104099360A (zh) * 2013-04-12 2014-10-15 北京大学 非天然氨基酸标记的目的蛋白或肽的制备
CN104120163B (zh) * 2013-04-28 2017-03-15 正大天晴药业集团股份有限公司 一种聚乙二醇修饰的蛋白质药物的修饰位点的测定方法
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
JP6702962B2 (ja) * 2014-10-24 2020-06-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改変ｆｇｆ−２１ポリペプチドおよびその使用
EP3309260A1 (en) 2016-10-14 2018-04-18 European Molecular Biology Laboratory Archaeal pyrrolysyl trna synthetases for orthogonal use
CN108220315A (zh) * 2016-12-22 2018-06-29 珠海冀百康生物科技有限公司 一种小分子蛋白或多肽的制备方法及融合蛋白
KR20190103256A (ko) 2016-12-30 2019-09-04 수트로박스, 인코포레이티드 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체
CN107033234B (zh) * 2017-01-03 2018-06-26 北京凯因科技股份有限公司 酰化的glp-1衍生物
AU2018215840A1 (en) * 2017-02-03 2019-08-01 Hanmi Pharm. Co., Ltd. Long-Acting Conjugate Of A Physiologically Active Material And Use Thereof

Also Published As

Publication number Publication date
CA3139826A1 (en) 2020-11-19
AU2020276560A1 (en) 2022-01-20
CN111909256A (zh) 2020-11-10
CN113811614A (zh) 2021-12-17
EP3967759A4 (en) 2023-08-23
US20220211857A1 (en) 2022-07-07
JP7453698B2 (ja) 2024-03-21
JP2022533066A (ja) 2022-07-21
WO2020228610A1 (zh) 2020-11-19
EP3967759A1 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
ECSP20025070A (es) Proteínas trispecificas y métodos de uso
BR112021022666A2 (pt) Frações de separação e seus métodos e uso
BR112018014028A2 (pt) anticorpos monoclonais anti-cd47 humanizados, de camundongo ou quimérico
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
MY202018A (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2020003959A (es) Metodos terapeuticos relacionados con los inhibidores de hsp90.
BR112013010834B1 (pt) polipeptídeos de fator ix modificados e usos dos mesmos
EP4257152A3 (en) Apelin polypeptides
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
BR112017005660A2 (pt) novos ativadores de guanilato ciclase solúvel e sua utilização
BR112016006048A8 (pt) composições antimicrobianas
BR112017016897A2 (pt) cepas fúngicas e métodos de uso
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
BR112021024978A2 (pt) Composições engajadoras específicas para macrófagos e métodos de uso das mesmas
BR112022019020A2 (pt) Proteínas de fusão de il12 mascaradas e métodos de uso das mesmas
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2022006533A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo.
BR112022012205A2 (pt) Compostos ativos para receptores nucleares
BR112021017957A2 (pt) Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo
BR112018070847A2 (pt) terapias combinadas para tratamento de câncer compreendendo um derivado de bacterioclorofila
MX2020010932A (es) Enzimas quinureninasa humanas y sus usos.
PH12016500708A1 (en) Recombinant glycoproteins and uses thereof
MX2022010093A (es) Tafoxiparina para el tratamiento de la preeclampsia.